1. Martelli, M, Ferreri, A, Di Rocco, A, et al. Primary mediastinal large B-cell lymphoma. Crit Rev Oncol Hematol 2017; 113: 318–327.
Google Scholar | Crossref | Medline2. Dunleavy, K. Primary mediastinal B-cell lymphoma: biology and evolving therapeutic strategies. Hematology Am Soc Hematol Educ Program 2017; 2017: 298–303.
Google Scholar | Crossref | Medline3. Broccoli, A, Zinzani, PL. The unique biology and treatment of primary mediastinal B-cell lymphoma. Best Pract Res Clin Haematol 2018; 31: 241–250.
Google Scholar | Crossref | Medline4. Dunleavy, K, Pittaluga, S, Maeda, LS, et al. Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma. N Engl J Med 2013; 368: 1408–1416.
Google Scholar | Crossref | Medline | ISI5. Aoki, T, Izutsu, K, Suzuki, R, et al. Prognostic significance of pleural or pericardial effusion and the implication of optimal treatment in primary mediastinal large B-cell lymphoma: a multicenter retrospective study in Japan. Haematologica 2014; 99: 1817–1825.
Google Scholar | Crossref | Medline6. Jiang, Y, Mo, W, Miao, Y, et al. Primary mediastinal large B cell lymphoma with coexisting aberrations of C-MYC and BCL-2: a case report and literature review. Med Mol Morphol 2020; 53: 124–129.
Google Scholar | Crossref | Medline7. Tatsumi, M, Kitayama, H, Sugahara, H, et al. Whole-body hybrid PET with 18F-FDG in the staging of non-Hodgkin's lymphoma. J Nucl Med 2001; 42: 601–608.
Google Scholar | Medline8. Rodriguez Taroco, MG, Cuna, EG, Pages, C, et al. Prognostic value of imaging markers from 18FDG-PET/CT in paediatric patients with Hodgkin lymphoma. Nucl Med Commun 2020.
Google Scholar9. Feng, X, Wen, X, Li, L, et al. Baseline Total Metabolic Tumor Volume and Total Lesion Glycolysis Measured on 18F-FDG PET-CT Predict Outcomes in T-Cell Lymphoblastic Lymphoma. Cancer Res Treat 2020.
Google Scholar10. Cottereau, AS, Meignan, M, Nioche, C, et al. Risk stratification in diffuse large B-cell lymphoma using lesion dissemination and metabolic tumor burden calculated from baseline PET/CT(dagger). Ann Oncol 2020.
Google Scholar | Medline11. Lin, DD, Shen, Y, Qiao, S, et al. Upregulation of OTUD7B (Cezanne) Promotes Tumor Progression via AKT/VEGF Pathway in Lung Squamous Carcinoma and Adenocarcinoma. Front Oncol 2019; 9: 862.
Google Scholar | Crossref | Medline12. Ceriani, L, Gritti, G, Cascione, L, et al. SAKK38/07 study: integration of baseline metabolic heterogeneity and metabolic tumor volume in DLBCL prognostic model. Blood Adv 2020; 4: 1082–1092.
Google Scholar | Crossref | Medline13. Liang, JH, Zhang, YP, Xia, J, et al. Prognostic Value of Baseline and Interim Total Metabolic Tumor Volume and Total Lesion Glycolysis Measured on 18F-FDG PET-CT in Patients with Follicular Lymphoma. Cancer Res Treat 2019; 51: 1479–1487.
Google Scholar | Crossref | Medline14. Meignan, M. Quantitative FDG-PET: a new biomarker in PMBCL. Blood 2015; 126: 924–926.
Google Scholar | Crossref | Medline15. von Elm, E, Altman, DG, Egger, M, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Ann Intern Med 2007; 147: 573–577.
Google Scholar | Crossref | Medline | ISI16. Shah, NN, Szabo, A, Huntington, SF, et al. R-CHOP versus dose-adjusted R-EPOCH in frontline management of primary mediastinal B-cell lymphoma: a multi-centre analysis. Br J Haematol 2018; 180: 534–544.
Google Scholar | Crossref | Medline17. Chan, EHL, Koh, LP, Lee, J, et al. Real world experience of R-CHOP with or without consolidative radiotherapy vs DA-EPOCH-R in the first-line treatment of primary mediastinal B-cell lymphoma. Cancer Med 2019; 8: 4626–4632.
Google Scholar | Crossref | Medline18. Bartlett, NL, Wilson, WH, Jung, SH, et al. Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303. J Clin Oncol 2019; 37: 1790–1799.
Google Scholar | Crossref | Medline19. Melani, C, Wilson, WH, Roschewski, M. What is the standard of care for primary mediastinal b-cell lymphoma; R-CHOP or DA-EPOCH-R? Br J Haematol 2019; 184: 836–838.
Google Scholar | Crossref | Medline20. Broccoli, A, Casadei, B, Stefoni, V, et al. The treatment of primary mediastinal large B-cell lymphoma: a two decades monocentric experience with 98 patients. BMC Cancer 2017; 17: 276.
Google Scholar | Crossref | Medline21. Goldschmidt, N, Kleinstern, G, Orevi, M, et al. Favorable outcome of primary mediastinal large B-cell lymphoma patients treated with sequential RCHOP-RICE regimen without radiotherapy. Cancer Chemother Pharmacol 2016; 77: 1053–1060.
Google Scholar | Crossref | Medline22. Malenda, A, Kolkowska-Lesniak, A, Pula, B, et al. Outcomes of treatment with dose-adjusted EPOCH-R or R-CHOP in primary mediastinal large B-cell lymphoma. Eur J Haematol 2020; 104: 59–66.
Google Scholar | Crossref | Medline23. Messmer, M, Tsai, HL, Varadhan, R, et al. R-CHOP without radiation in frontline management of primary mediastinal B-cell lymphoma. Leuk Lymphoma 2019; 60: 1261–1265.
Google Scholar | Crossref | Medline24. Zhou, H, Xu-Monette, ZY, Xiao, L, et al. Prognostic factors, therapeutic approaches, and distinct immunobiologic features in patients with primary mediastinal large B-cell lymphoma on long-term follow-up. Blood Cancer J 2020; 10: 49.
Google Scholar | Crossref | Medline25. Cheson, BD, Fisher, RI, Barrington, SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 2014; 32: 3059–3068.
Google Scholar | Crossref | Medline | ISI26. Cheson, BD. Staging and response assessment in lymphomas: the new Lugano classification. Chin Clin Oncol 2015; 4: 5.
Google Scholar | Medline27. Melani, C, Advani, R, Roschewski, M, et al. End-of-treatment and serial PET imaging in primary mediastinal B-cell lymphoma following dose-adjusted EPOCH-R: a paradigm shift in clinical decision making. Haematologica 2018; 103: 1337–1344.
Google Scholar | Crossref | Medline28. Martelli, M, Ceriani, L, Zucca, E, et al. [18F]fluorodeoxyglucose positron emission tomography predicts survival after chemoimmunotherapy for primary mediastinal large B-cell lymphoma: results of the International Extranodal Lymphoma Study Group IELSG-26 Study. J Clin Oncol 2014; 32: 1769–1775.
Google Scholar | Crossref | Medline29. Ceriani, L, Martelli, M, Zinzani, PL, et al. Utility of baseline 18FDG-PET/CT functional parameters in defining prognosis of primary mediastinal (thymic) large B-cell lymphoma. Blood 2015; 126: 950–956.
Google Scholar | Crossref | Medline30. Bledsoe, JR, Redd, RA, Hasserjian, RP, et al. The immunophenotypic spectrum of primary mediastinal large B-cell lymphoma reveals prognostic biomarkers associated with outcome. Am J Hematol 2016; 91: E436–E441.
Google Scholar | Crossref | Medline31. Mottok, A, Hung, SS, Chavez, EA, et al. Integrative genomic analysis identifies key pathogenic mechanisms in primary mediastinal large B-cell lymphoma. Blood 2019; 134: 802–813.
Google Scholar | Crossref | Medline32. Halford, Z, Anderson, MK, Bennett, LL. Axicabtagene Ciloleucel: Clinical Data for the Use of CAR T-cell Therapy in Relapsed and Refractory Large B-cell Lymphoma. Ann Pharmacother 2021; 55: 390–405.
Google Scholar | SAGE Journals | ISI33. Nijland, M, van Meerten, T, Seitz, A, et al. Combined PD-1 and JAK1/2 inhibition in refractory primary mediastinal B-cell lymphoma. Ann Hematol 2018; 97: 905–907.
Google Scholar | Medline34. Zinzani, PL, Ribrag, V, Moskowitz, CH, et al. Safety and tolerability of pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma. Blood 2017; 130: 267–270.
Google Scholar | Crossref | Medline35. Zinzani, PL, Pellegrini, C, Chiappella, A, et al. Brentuximab vedotin in relapsed primary mediastinal large B-cell lymphoma: results from a phase 2 clinical trial. Blood 2017; 129: 2328–2330.
Google Scholar | Crossref | Medline